Breast carcinomas expressing basal markers have poor clinical outcome regardless of estrogen receptor status
- Authors
- Shin, Bong Kyung; Lee, Youngseok; Lee, Jung Bok; Kim, Han Kyeom; Lee, Jae Bok; Cho, Su Jin; Kim, Aeree
- Issue Date
- 3월-2008
- Publisher
- SPANDIDOS PUBL LTD
- Keywords
- basal; breast carcinoma; gene expression profile; immunohistochemistry
- Citation
- ONCOLOGY REPORTS, v.19, no.3, pp.617 - 625
- Indexed
- SCIE
SCOPUS
- Journal Title
- ONCOLOGY REPORTS
- Volume
- 19
- Number
- 3
- Start Page
- 617
- End Page
- 625
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/123928
- ISSN
- 1021-335X
- Abstract
- To evaluate the clinical significance of gene expression-based classification and define the characteristic features of the new basal-like subtype, invasive breast carcinomas were divided into ER, HER2, basal-like and null subtypes by immunohistochemical analysis. A total of 401 invasive breast carcinomas were submitted to tissue microarray and stained with ER, HER2, EGFR, c-KIT and cytokeratin (CK) 5/6. The basal-like tumors, defined as positive for one or more basal markers but negative for both ER and HER2, comprised 18.5%. They were larger (p=0.041), showed higher grade (p<0.001), and more frequently expressed p53 (p=0.003). Expression of the basal marker itself showed negative prognostic effect, particularly in node-positive group. Even ER-positive patients had far shorter disease-free survival (DFS) when the tumor coexpressed one or more basal marker (p<0.001). Discrimination of basal-like subtype or tumors positive for basal markers may be clinically significant also in the treatment and prognosis of breast carcinomas.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
- Graduate School > Department of Biomedical Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.